Shumar John, Junga Zachary, Johnson Jeptha T, Goldkind Lawrence
Internal Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland, USA
Gastroenterology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
BMJ Case Rep. 2019 Dec 1;12(11):e231544. doi: 10.1136/bcr-2019-231544.
Chemotherapy-induced diarrhoea (CID) is a risk of antineoplastic regimens, often associated with 5-fluorouracil (5-FU), irinotecan and capecitabine. Current treatment guidelines for CID include the use of loperamide and octreotide but do not account for other therapies, including budesonide. Small case reports have shown benefit with budesonide in CID secondary to 5-FU and irinotecan, but there is no literature base addressing budesonide use in CID secondary to capecitabine. We describe a case of a patient with severe capecitabine-induced diarrhoea that was refractory to guideline based therapy but resolved with the use of budesonide.
化疗引起的腹泻（CID）是抗肿瘤治疗方案的一种风险，常与5-氟尿嘧啶（5-FU）、伊立替康和卡培他滨相关。目前CID的治疗指南包括使用洛哌丁胺和奥曲肽，但未考虑其他疗法，包括布地奈德。小型病例报告显示布地奈德对5-FU和伊立替康继发的CID有益，但尚无关于布地奈德用于卡培他滨继发CID的文献依据。我们描述了一例严重卡培他滨诱导的腹泻患者，该患者对基于指南的治疗无效，但使用布地奈德后腹泻得到缓解。
